Richard James Gilbertson is a Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge.[1] He is the Li Ka Shing Chair of Oncology,[2] and Director of the CRUK Cambridge Major Centre[3] and the Children's Brain Tumour Centre of Excellence.[4]
Gilbertson's research focuses on understanding the link between normal development and the origins of cancer, with a particular focus on children's brain tumours.[8] He has shown that clinically distinct subtypes of childhood medulloblastoma and ependymoma arise within different lineages of developing brain and are driven by distinct mutations in their DNA.[9][10][11][12] His work has also shown that a combination of stem cellmutagenesis and extrinsic factors that enhance the proliferation of progenitor cell populations across multiple organs ultimately determines organ cancer risk.[13][14]
In 2000, Gilbertson joined the St Jude Children's Research Hospital in Memphis, Tennessee.[15] There, he became the founding director of the Molecular Clinical Trials Core and the co-leader of the Neurobiology and Brain Tumor Program.[16] In 2011, he was named executive vice president of St. Jude and director of its Comprehensive Cancer Centre.[7][17][18] In 2014 he was also appointed Scientific Director of St. Jude Children's Research Hospital.
In 2015, he returned to the UK as the Li Ka Shing Chair of Oncology, head of the Department of Oncology, senior group leader at the Cancer Research UK Cambridge Institute at the University of Cambridge and Director of the CRUK Cambridge Major Centre.[19]
He was elected: Fellow of the Academy of Medical Sciences (FMedSci) in 2017;[20] Fellow of the European Academy of Cancer Sciences in 2017;[21] and Fellow of the Royal Society of London (FRS) in 2022.[22] His certificate for election to Fellow of the Royal Society reads:
Richard has pioneered the field of cross-species genomics, deploying data generated from patients to identify the lineage origins of childhood brain tumours; build accurate models of these cancers; and design new treatments. He has also generated organism-wide maps of cancer risk across all organs and ages, helping to understand the relative contributions of cell lineage, gene mutation and tissue damage to tumourigenesis.[23]
^"ALSF CORD Fund History". Alex's Lemonade Stand Foundation for Childhood Cancer. 7 March 2019. Archived from the original on 18 March 2015. Retrieved 6 June 2019.
